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STATE-OF-THE-ART PAPER STATE-OF-THE-ART PAPER511HIV and Coronary Heart DiseaseFranck Boccara, Sylvie Lang, Catherine Meuleman, Stephane Ederhy, Murielle Mary-Krause,
Dominique Costagliola, Jacqueline Capeau, Ariel Cohen
Since the advent of efficient antiretroviral therapies and the consequent longer patient
lifespan, an increased risk of myocardial infarction has been observed in HIV-infected patients
compared with the general population in Western countries. The pathophysiology of this
accelerated atherosclerotic process is complex and multifactorial, with contributions from
traditional cardiovascular risk factors, side effects of antiretroviral drugs, and chronic
inflammation. Bocarra and colleagues review the pathophysiology of HIV and coronary heart
disease and call on physicians to more aggressively target traditional risk factors starting at age
45 years and possibly, younger.CLINICAL RESEARCH CLINICAL TRIAL524Buproprion Ineffective for Smoking Cessation in Patients Hospitalized With AMIMark J. Eisenberg, Sonia M. Grandi, André Gervais, Jennifer O’Loughlin, Gilles Paradis,
Stéphane Rinfret, Nizal Sarrafzadegan, Sat Sharma, Claude Lauzon, Rakesh Yadav,
Louise Pilote, for the ZESCA Investigators
Bupropion doubles quit rates in otherwise healthy smokers and patients with stable
cardiovascular disease, but its safety and efficacy in patients with acute myocardial infarction
(AMI) is unresolved. Eisenberg and colleagues conducted a multicenter, double-blind,
placebo-controlled, randomized trial in smokers hospitalized with AMI. Participants received
bupropion or placebo for 9 weeks and were followed for 12 months. At 12 months, there
were no significant differences in cessation rates, nor major adverse cardiovascular events.
These results show that two-thirds of patients return to smoking by 12 months after AMI;
bupropion appears to be safe in the immediate post-AMI period, but does not increase the
rates of smoking cessation.
Editorial Comment: Neal L. Benowitz, Judith J. Prochaska, page 533(continued on page A-26)
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536afety and Efficacy of Second-Generation Xience V EES
Versus Resolute ZES in Real-World PracticeKyung Woo Park, Joo Myung Lee, Si-Hyuck Kang, Hyo-Suk Ahn, Han-Mo Yang, Hae-Young Lee,
Hyun-Jae Kang, Bon-Kwon Koo, Janghyun Cho, Hyeon-Cheol Gwon, Sung Yoon Lee, In-Ho Chae,
Tae-Jin Youn, Jei Keon Chae, Kyoo-Rok Han, Cheol Woong Yu, Hyo-Soo Kim
Woo Park and colleagues compared the safety and efficacy of everolimus-eluting
stents (EES) with zotarolimus-eluting stents (ZES) in “all-comer” cohorts. Two stent
registries enrolled over 5,000 patients without exclusions, with three-fourths of
patients having “off-label” indications. There were no significant differences in either
stent-related outcomes such as target lesion failure or in the patient-related
outcomes. There were also no differences in rates of definite or probable stent
thrombosis. In this real-world registry with unrestricted use of EES and ZES, the
stents showed comparable safety and efficacy at 1-year follow-up.INTERVENTIONAL CARDIOLOGY545Predictors of Reocclusion After Successful PCI of CTORenato Valenti, Ruben Vergara, Angela Migliorini, Guido Parodi, Nazario Carrabba, Giampaolo Cerisano,
Emilio Vincenzo Dovellini, David Antoniucci
Valenti and colleagues reviewed data from the Florence CTO PCI Registry to determine the
incidence of reocclusion and to identify predictors of angiographic failure after successful
chronic total occlusion (CTO) drug-eluting stent (DES) supported percutaneous coronary
intervention (PCI). Over 1,000 patients underwent PCI for at least 1 CTO with 77% having
a successful PCI. The reocclusion rate was 7.5%, while the binary restenosis or reocclusion
rate was 20%. Everolimus-eluting stents (EES) were associated with a significantly lower
reocclusion rate than other DES. An initially successful STAR technique, subintimal tracking
and reentry, was followed by a 57% of reocclusion rate. By multivariable analysis STAR
technique (odds ratio: 29.5) and EES (odds ratio: 0.22) were independently related to the risk
of reocclusion.
Editorial Comment: Joachim Schofer, page 551(continued on page A-27)
FEBRUARY 5, 2013 (continued) A-27CARDIOMETABOLIC RISK553Central Obesity More Predictive of Cardiac Risk than BMIThais Coutinho, Kashish Goel, Daniel Corrêa de Sa´, Rickey E. Carter, David O. Hodge,
Charlotte Kragelund, Alka M. Kanaya, Marianne Zeller, Jong Seon Park, Lars Kober,
Christian Torp-Pedersen, Yves Cottin, Luc Lorgis, Sang-Hee Lee, Young-Jo Kim, Randal Thomas,
Véronique L. Roger, Virend K. Somers, Francisco Lopez-Jimenez
Coutinho and colleagues studied the contributions of body mass index (BMI) and central
obesity to cardiac risk in patients with coronary artery disease (CAD). Data from 15,547
participants with CAD who were part of 5 studies from 3 continents were combined. The
results showed that subjects who have a normal BMI but are in the highest quintiles of
central obesity, as measured by the waist-to-hip ratio, have higher mortality risk than any
other combination of BMI and central obesity. Conversely, subjects who had a BMI in the
overweight or obese categories but were in the lowest quintile of central obesity had the
lowest mortality. These results suggest that in patients with CAD, central obesity, rather than
BMI, mediates cardiac risk.CONGENITAL HEART DISEASE561Serial Magnetic Resonance Imaging in Hypoplastic Left Heart SyndromeHannah R. Bellsham-Revell, Shane M. Tibby, Aaron J. Bell, Thomas Witter, John Simpson,
Philipp Beerbaum, David Anderson, Conal B. Austin, Gerald F. Greil, Reza Razavi
Bellsham-Revell and colleagues investigated changes in ventricular volumes and vascular
dimensions before hemi-Fontan (HF) and prior to total cavo-pulmonary connection (TCPC)
in children with hypoplastic left heart syndrome (HLHS). A total of 58 patients had paired
pre-HF and pre-TCPC cardiac magnetic resonance imaging studies. The results showed a
decrease of indexed right ventricular (RV) end-diastolic volume (iEDV) and end-systolic
volume with stroke volume remaining constant leading to an increased RV ejection fraction
(51% vs. 59%). iEDV plotted against neo-aortic stroke volume demonstrated a Frank-Starling
like curve that shifted upwards after HF. In HLHS serial MRI shows the adaptation of the
systemic RV following HF.(continued on page A-28)









571elationship Between Clinical Trial Site Enrollment With
Participant Characteristics, Protocol Completion, and OutcomesJaved Butler, Haris Subacius, Muthiah Vaduganathan, Gregg C. Fonarow, Andrew P. Ambrosy,
Marvin A. Konstam, Aldo Maggioni, Robert J. Mentz, Karl Swedberg, Faiez Zannad, Mihai Gheorghiade,
on behalf of the EVEREST Investigators
Butler and colleagues investigated whether the number of participants enrolled per site in an
acute heart failure trial is associated with participant characteristics and outcomes. A total of
4,133 participants enrolled in the Everest Trial from 359 sites were grouped based on total
enrollment into 1 to 10, 11 to 30, and 30 participants per site. Subjects from sites with
ewer enrollments were more likely to be older, males, have lower ejection fraction and blood
ressure, worse comorbidities, and less likely to be on angiotensin-converting enzyme
nhibitors or aldosterone antagonists. Compared to the event rate at sites with 30
articipants, subjects at sites with 1 to 10 and 11 to 30 participants had worse outcomes, even
fter multivariable adjustment. Sites with higher enrollment also had higher rates of protocol
ompletion. These data imply that the number of participants enrolled per site may influence
rials beyond logistics.ditorial Comment: Deepak L. Bhatt, Matthew A. Cavender, page 580PRE-CLINICAL RESEARCH PRE-CLINICAL RESEARCH
582ranilast Prevents AF in a Canine Model of Atrial Tachycardia
and Left Ventricular DysfunctionYosuke Nakatani, Kunihiro Nishida, Masao Sakabe, Naoya Kataoka, Tamotsu Sakamoto, Yoshiaki Yamaguchi,
Jotaro Iwamoto, Koichi Mizumaki, Akira Fujiki, Hiroshi Inoue
Tranilast has been shown to prevent ventricular fibrosis in hypertensive and diabetic
cardiomyopathy models. Nakatani and colleagues. studied the effects of tranilast on atrial
remodelling in a canine atrial fibrillation (AF) model. Beagles were subjected to atrial
tachypacing for 4 weeks while treated with placebo or tranilast. Tranilast decreased the
changes seen in AF duration, AF cycle length, and atrial effective refractory period compared
to controls. There was also less atrial fibrosis and increased expression of tissue inhibitor of
metalloproteinase protein 1 in tranilast treated dogs. Tranilast prevents atrial remodelling and
AF development in a canine tachypacing model.
